Radiation proctitis primary prevention
|
Radiation proctitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Radiation proctitis primary prevention On the Web |
|
American Roentgen Ray Society Images of Radiation proctitis primary prevention |
|
Risk calculators and risk factors for Radiation proctitis primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Overview
Primary Prevention
Primary prevention strategies include: [1]
- modifications of radiation techniques and doses (Ex: intensity-modulated radiation therapy, image-guided radiation therapy decreases the rectal toxicity while maximizing the dose to the tumor.)[2]
- Identifying high risk patients, based on genomic study helps taking extra precautions in those patients[3][4]
- Use of adjuvant medical treatment (Ex: amifostine, sucralfate, 5-aminosalicylic acid, or sulphasalazine) have been associated with the minimal effect and are rarely used.[5]
References
- ↑ Hille A, Christiansen H, Pradier O, Hermann RM, Siekmeyer B, Weiss E; et al. (2005). "Effect of pentoxifylline and tocopherol on radiation proctitis/enteritis". Strahlenther Onkol. 181 (9): 606–14. doi:10.1007/s00066-005-1390-y. PMID 16170489.
- ↑ Fonteyne V, De Neve W, Villeirs G, De Wagter C, De Meerleer G (2007). "Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity". Radiother Oncol. 84 (2): 156–63. doi:10.1016/j.radonc.2007.06.013. PMID 17692976.
- ↑ Fachal L, Gómez-Caamaño A, Barnett GC, Peleteiro P, Carballo AM, Calvo-Crespo P; et al. (2014). "A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1". Nat Genet. 46 (8): 891–4. doi:10.1038/ng.3020. PMID 24974847.
- ↑ West CM, Barnett GC (2011). "Genetics and genomics of radiotherapy toxicity: towards prediction". Genome Med. 3 (8): 52. doi:10.1186/gm268. PMC 3238178. PMID 21861849.
- ↑ Stellamans K, Lievens Y, Lambin P, Van den Weyngaert D, Van den Bogaert W, Scalliet P; et al. (2002). "Does sucralfate reduce early side effects of pelvic radiation? A double-blind randomized trial". Radiother Oncol. 65 (2): 105–8. PMID 12443806.